Atlas Trials

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Clinical trial NCT06844357 · RECRUITING

Trial details

NCT number
NCT06844357
Sponsor
Zhejiang Raygene Pharmaceuticals Co., Ltd
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
HCC
Start date
2025-03-27
Primary completion
2029-04-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.